Successful provision of CAR-T therapy during a pandemic: low SARS-CoV-2 infection rates and reduction in ICU admissions following modification of patient pathway

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors thank all the staff who have shown dedication in delivering a high standard of care to patients throughout the pandemic. Special thanks also to their critical care colleagues, but most importantly the authors extend their thanks to the patients undergoing CAR-T therapy during these challenging times.

Disclosure statement

Novartis, Kite/Gilead (speaker and consultancy fees).